{"id":338142,"date":"2026-11-04T10:38:11","date_gmt":"2026-11-04T05:08:11","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=338142"},"modified":"2026-11-04T10:38:11","modified_gmt":"2026-11-04T05:08:11","slug":"mumbai-stocks-to-buy","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/mumbai-stocks-to-buy\/","title":{"rendered":"Mumbai Stocks to Buy in November 2026: 5 Names on the Watchlist"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>L&#038;T Rs 3,948. Sun Pharma Rs 1,770. Phoenix Rs 2,049. Ajanta Pharma Rs 3,320. Ipca Labs Rs 1,950. NSE closing prices, 3 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Five Mumbai stocks to buy on the November 2026 watchlist are Larsen and Toubro, Sun Pharmaceutical Industries, Phoenix Mills, Ajanta Pharma and Ipca Laboratories. All five grew revenue in their latest full year, and all five also grew net profit. Larsen and Toubro has the lowest P\/E at 25.06, while Ajanta Pharma leads on return on equity at 23.33%. Check each valuation against your own risk appetite before acting.<\/p>\n<\/p><\/div>\n<p>The Mumbai stocks to buy in November 2026 start with five listed names: Larsen and Toubro, Sun Pharmaceutical Industries, Phoenix Mills, Ajanta Pharma and Ipca Laboratories. Mumbai stocks are listed companies headquartered in India&#8217;s financial capital, spanning engineering, pharma and real estate.<\/p>\n<p>This article ranks none of them as a sure thing. It lays out the numbers each company has reported, how the shares are priced today and what an investor should check before adding any of these Mumbai stocks to buy to a portfolio. All prices are NSE closing prices of 3 November 2026, and financials come from company filings.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=mumbai-stocks-to-buy\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/mumbai-stocks-to-buy\/#Which_Are_the_Best_Mumbai_Stocks_to_Buy_in_November_2026\" title=\"Which Are the Best Mumbai Stocks to Buy in November 2026?\">Which Are the Best Mumbai Stocks to Buy in November 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/mumbai-stocks-to-buy\/#Why_These_Mumbai_Stocks_to_Buy_Are_in_Focus\" title=\"Why These Mumbai Stocks to Buy Are in Focus\">Why These Mumbai Stocks to Buy Are in Focus<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/mumbai-stocks-to-buy\/#Larsen_and_Toubro_The_Infrastructure_Conglomerate_Among_Mumbai_Stocks_to_Buy\" title=\"Larsen and Toubro: The Infrastructure Conglomerate Among Mumbai Stocks to Buy\">Larsen and Toubro: The Infrastructure Conglomerate Among Mumbai Stocks to Buy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/mumbai-stocks-to-buy\/#Sun_Pharmaceutical_Industries_The_Pharma_Heavyweight_Among_Mumbai_Stocks_to_Buy\" title=\"Sun Pharmaceutical Industries: The Pharma Heavyweight Among Mumbai Stocks to Buy\">Sun Pharmaceutical Industries: The Pharma Heavyweight Among Mumbai Stocks to Buy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/mumbai-stocks-to-buy\/#Phoenix_Mills_The_Mall_Owner_Among_Mumbai_Stocks_to_Buy\" title=\"Phoenix Mills: The Mall Owner Among Mumbai Stocks to Buy\">Phoenix Mills: The Mall Owner Among Mumbai Stocks to Buy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/mumbai-stocks-to-buy\/#Ajanta_Pharma_The_Branded_Generics_Specialist_Among_Mumbai_Stocks_to_Buy\" title=\"Ajanta Pharma: The Branded Generics Specialist Among Mumbai Stocks to Buy\">Ajanta Pharma: The Branded Generics Specialist Among Mumbai Stocks to Buy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/mumbai-stocks-to-buy\/#Ipca_Laboratories_The_Formulations_and_API_Name_Among_Mumbai_Stocks_to_Buy\" title=\"Ipca Laboratories: The Formulations and API Name Among Mumbai Stocks to Buy\">Ipca Laboratories: The Formulations and API Name Among Mumbai Stocks to Buy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/mumbai-stocks-to-buy\/#Growth_Snapshot_Latest_Full_Year_and_Latest_Quarter\" title=\"Growth Snapshot: Latest Full Year and Latest Quarter\">Growth Snapshot: Latest Full Year and Latest Quarter<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/mumbai-stocks-to-buy\/#Factors_That_Move_Mumbai_Stocks_to_Buy\" title=\"Factors That Move Mumbai Stocks to Buy\">Factors That Move Mumbai Stocks to Buy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/mumbai-stocks-to-buy\/#Risks_to_Keep_in_Mind_Before_Buying_Mumbai_Stocks\" title=\"Risks to Keep in Mind Before Buying Mumbai Stocks\">Risks to Keep in Mind Before Buying Mumbai Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/mumbai-stocks-to-buy\/#How_to_Choose_Mumbai_Stocks_to_Buy\" title=\"How to Choose Mumbai Stocks to Buy\">How to Choose Mumbai Stocks to Buy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/mumbai-stocks-to-buy\/#How_to_Invest_in_Mumbai_Stocks\" title=\"How to Invest in Mumbai Stocks\">How to Invest in Mumbai Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/mumbai-stocks-to-buy\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/mumbai-stocks-to-buy\/#Frequently_Asked_Questions_on_Mumbai_Stocks_to_Buy\" title=\"Frequently Asked Questions on Mumbai Stocks to Buy\">Frequently Asked Questions on Mumbai Stocks to Buy<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/mumbai-stocks-to-buy\/#Which_are_the_best_Mumbai_stocks_to_buy_in_November_2026\" title=\"Which are the best Mumbai stocks to buy in November 2026?\">Which are the best Mumbai stocks to buy in November 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/mumbai-stocks-to-buy\/#Is_Larsen_and_Toubro_a_good_stock_to_buy_from_this_Mumbai_list\" title=\"Is Larsen and Toubro a good stock to buy from this Mumbai list?\">Is Larsen and Toubro a good stock to buy from this Mumbai list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/mumbai-stocks-to-buy\/#Are_these_Mumbai_stocks_expensive_right_now\" title=\"Are these Mumbai stocks expensive right now?\">Are these Mumbai stocks expensive right now?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/mumbai-stocks-to-buy\/#Which_of_these_Mumbai_stocks_pay_a_dividend\" title=\"Which of these Mumbai stocks pay a dividend?\">Which of these Mumbai stocks pay a dividend?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/mumbai-stocks-to-buy\/#Which_stock_on_this_list_has_the_highest_return_on_equity\" title=\"Which stock on this list has the highest return on equity?\">Which stock on this list has the highest return on equity?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/mumbai-stocks-to-buy\/#What_are_the_risks_of_investing_in_Mumbai_stocks\" title=\"What are the risks of investing in Mumbai stocks?\">What are the risks of investing in Mumbai stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/mumbai-stocks-to-buy\/#How_can_I_invest_in_Mumbai_stocks_in_India\" title=\"How can I invest in Mumbai stocks in India?\">How can I invest in Mumbai stocks in India?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Which_Are_the_Best_Mumbai_Stocks_to_Buy_in_November_2026\"><\/span><strong>Which Are the Best Mumbai Stocks to Buy in November 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The best Mumbai stocks to buy in November 2026 for a watchlist are Larsen and Toubro, Sun Pharmaceutical Industries, Phoenix Mills, Ajanta Pharma and Ipca Laboratories. They were picked because each has complete reported financials, profit in the latest quarter and an NSE listing. The table puts their market data side by side.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"6\">\n<thead>\n<tr>\n<th>Company<\/th>\n<th>CMP (Rs)<\/th>\n<th>Market Cap<\/th>\n<th>P\/E<\/th>\n<th>ROE<\/th>\n<th>Dividend Yield<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><a href=\"https:\/\/univest.in\/stocks\/lt\/larsen-and-toubro-ltd-share-price-today\">Larsen and Toubro<\/a><\/td>\n<td>3,948<\/td>\n<td>Rs 5,23,536 crore<\/td>\n<td>25.06<\/td>\n<td>15.81%<\/td>\n<td>1.00%<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/univest.in\/stocks\/sunpharma\/sun-pharmaceutical-industries-ltd-share-price-today\">Sun Pharmaceutical Industries<\/a><\/td>\n<td>1,770<\/td>\n<td>Rs 4,22,991 crore<\/td>\n<td>34.91<\/td>\n<td>13.74%<\/td>\n<td>0.91%<\/td>\n<\/tr>\n<tr>\n<td>Phoenix Mills<\/td>\n<td>2,049<\/td>\n<td>Rs 70,465 crore<\/td>\n<td>43.23<\/td>\n<td>11.14%<\/td>\n<td>0.13%<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/univest.in\/stocks\/ajantpharm\/ajanta-pharma-ltd-share-price-today\">Ajanta Pharma<\/a><\/td>\n<td>3,320<\/td>\n<td>Rs 43,234 crore<\/td>\n<td>38.10<\/td>\n<td>23.33%<\/td>\n<td>0.81%<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/univest.in\/stocks\/ipcalab\/ipca-laboratories-ltd-share-price-today\">Ipca Laboratories<\/a><\/td>\n<td>1,950<\/td>\n<td>Rs 48,860 crore<\/td>\n<td>35.53<\/td>\n<td>14.15%<\/td>\n<td>0.31%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>On valuation, Sun Pharmaceutical Industries, Ajanta Pharma and Ipca Laboratories sit close to it; Larsen and Toubro and Phoenix Mills carry a premium. Valuation is the first filter for any Mumbai stocks to buy list, and it is covered again in the risk section.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_These_Mumbai_Stocks_to_Buy_Are_in_Focus\"><\/span><strong>Why These Mumbai Stocks to Buy Are in Focus<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Mumbai is home to the head offices of many of India&#8217;s largest listed companies. The list covers an engineering and construction conglomerate, India&#8217;s largest pharmaceutical company by market value, a retail-led mall developer, a branded generics company and a formulations and active ingredients maker. Investors comparing the best Mumbai stocks in India usually check earnings growth, margins and valuation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Larsen_and_Toubro_The_Infrastructure_Conglomerate_Among_Mumbai_Stocks_to_Buy\"><\/span><strong>Larsen and Toubro: The Infrastructure Conglomerate Among Mumbai Stocks to Buy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Larsen and Toubro is an engineering and construction conglomerate spanning infrastructure, defence, energy and IT services. At Rs 3,948, the stock has a market capitalisation of Rs 5,23,536 crore and trades at 25.06 times earnings, while the industry P\/E is 21.53.<\/p>\n<p>Reported numbers show FY26 revenue of Rs 2,91,635 crore, up 12.2% year on year, with net profit at Rs 19,159 crore, up 8.3%. The September 2026 quarter added revenue of Rs 81,056 crore (up 16.8%) and net profit of Rs 5,915 crore (up 26.2%).<\/p>\n<p>Return on equity is 15.81%, debt-to-equity is 1.24, and the dividend yield is 1.00%. The company has no identified promoter, with foreign institutions holding 19.21% and domestic institutions 42.86% as of September 2026. A point to keep in view: debt is higher than most names on this list.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Sun_Pharmaceutical_Industries_The_Pharma_Heavyweight_Among_Mumbai_Stocks_to_Buy\"><\/span><strong>Sun Pharmaceutical Industries: The Pharma Heavyweight Among Mumbai Stocks to Buy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Sun Pharmaceutical Industries is India&#8217;s largest pharmaceutical company by market value, with a strong domestic franchise and a growing specialty portfolio in the US. Its market capitalisation is Rs 4,22,991 crore, the share price is Rs 1,770 and the P\/E of 34.91 compares with an industry P\/E of 37.65.<\/p>\n<p>Over FY26, net profit rose 5.3% to Rs 11,565 crore on revenue of Rs 61,674 crore, which was up 12.7%. The latest quarter, the June 2026 quarter, brought revenue of Rs 16,024 crore, up 11.9% year on year, and net profit of Rs 2,911 crore, up 26.4%.<\/p>\n<p>Return on equity is 13.74%, debt-to-equity is 0.06, and the dividend yield is 0.91%. Promoters hold 52.68%, foreign institutions 14.36% and domestic institutions 22.27% as of September 2026. Domestic institutional holding has risen from 20.23% to 22.27% over the last year.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Mumbai Stocks Live on the Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Phoenix_Mills_The_Mall_Owner_Among_Mumbai_Stocks_to_Buy\"><\/span><strong>Phoenix Mills: The Mall Owner Among Mumbai Stocks to Buy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Phoenix Mills is a retail-led developer that owns and operates large malls. The stock trades at Rs 2,049 with a market capitalisation of Rs 70,465 crore and a P\/E of 43.23, against an industry P\/E of 31.04.<\/p>\n<p>FY26 revenue rose 15.9% to Rs 4,594 crore and net profit rose 19.6% to Rs 1,557 crore. In the June 2026 quarter, revenue grew 13.3% year on year to Rs 1,115 crore, while net profit grew 23.0% to Rs 394 crore.<\/p>\n<p>Return on equity is 11.14%, debt-to-equity is 0.48, and the dividend yield is 0.13%. Promoters hold 47.24%, foreign institutions 31.62% and domestic institutions 17.31% as of September 2026. Domestic institutional holding has risen from 15.47% to 17.31% over the last year.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Ajanta_Pharma_The_Branded_Generics_Specialist_Among_Mumbai_Stocks_to_Buy\"><\/span><strong>Ajanta Pharma: The Branded Generics Specialist Among Mumbai Stocks to Buy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Ajanta Pharma is a branded generics company with a strong presence in dermatology, ophthalmology and cardiology in India, Africa and Asia. At Rs 3,320, the stock has a market capitalisation of Rs 43,234 crore and trades at 38.10 times earnings, while the industry P\/E is 37.65.<\/p>\n<p>Reported numbers show FY26 revenue of Rs 5,625 crore, up 18.6% year on year, with net profit at Rs 1,056 crore, up 14.7%. The June 2026 quarter added revenue of Rs 1,697 crore (up 27.7%) and net profit of Rs 334 crore (up 30.9%).<\/p>\n<p>Return on equity is 23.33%, debt-to-equity is 0.06, and the dividend yield is 0.81%. Promoters hold 63.47%, foreign institutions 7.63% and domestic institutions 21.94% as of September 2026. Domestic institutional holding has risen from 17.90% to 21.94% over the last year.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Ipca_Laboratories_The_Formulations_and_API_Name_Among_Mumbai_Stocks_to_Buy\"><\/span><strong>Ipca Laboratories: The Formulations and API Name Among Mumbai Stocks to Buy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Ipca Laboratories is a pharma company making formulations and active ingredients, known for anti-malarial and pain-management products. Its market capitalisation is Rs 48,860 crore, the share price is Rs 1,950 and the P\/E of 35.53 compares with an industry P\/E of 37.65.<\/p>\n<p>Over FY26, net profit rose 51.3% to Rs 1,191 crore on revenue of Rs 9,821 crore, which was up 8.7%. The latest quarter, the June 2026 quarter, brought revenue of Rs 2,813 crore, up 20.2% year on year, and net profit of Rs 423 crore, up 80.4%.<\/p>\n<p>Return on equity is 14.15%, debt-to-equity is 0.10, and the dividend yield is 0.31%. Promoters hold 44.72%, foreign institutions 11.53% and domestic institutions 36.59% as of September 2026. Foreign institutional holding has risen from 10.43% to 11.53% over the last year.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track these Mumbai stocks live and get daily stock recommendations.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Growth_Snapshot_Latest_Full_Year_and_Latest_Quarter\"><\/span><strong>Growth Snapshot: Latest Full Year and Latest Quarter<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table compares year-on-year growth in revenue and net profit for all five Mumbai stocks, using filed results.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"6\">\n<thead>\n<tr>\n<th>Company<\/th>\n<th>Full-Year Revenue Growth<\/th>\n<th>Full-Year Profit Growth<\/th>\n<th>Latest Quarter<\/th>\n<th>Quarter Revenue Growth<\/th>\n<th>Quarter Profit Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Larsen and Toubro<\/td>\n<td>12.2%<\/td>\n<td>8.3%<\/td>\n<td>Sep 2026<\/td>\n<td>16.8%<\/td>\n<td>26.2%<\/td>\n<\/tr>\n<tr>\n<td>Sun Pharmaceutical Industries<\/td>\n<td>12.7%<\/td>\n<td>5.3%<\/td>\n<td>Jun 2026<\/td>\n<td>11.9%<\/td>\n<td>26.4%<\/td>\n<\/tr>\n<tr>\n<td>Phoenix Mills<\/td>\n<td>15.9%<\/td>\n<td>19.6%<\/td>\n<td>Jun 2026<\/td>\n<td>13.3%<\/td>\n<td>23.0%<\/td>\n<\/tr>\n<tr>\n<td>Ajanta Pharma<\/td>\n<td>18.6%<\/td>\n<td>14.7%<\/td>\n<td>Jun 2026<\/td>\n<td>27.7%<\/td>\n<td>30.9%<\/td>\n<\/tr>\n<tr>\n<td>Ipca Laboratories<\/td>\n<td>8.7%<\/td>\n<td>51.3%<\/td>\n<td>Jun 2026<\/td>\n<td>20.2%<\/td>\n<td>80.4%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Factors_That_Move_Mumbai_Stocks_to_Buy\"><\/span><strong>Factors That Move Mumbai Stocks to Buy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Four factors tend to drive Mumbai stocks, and each one is worth checking before a purchase.<\/p>\n<ul>\n<li><strong>Order books:<\/strong> Engineering firms depend on project orders.<\/li>\n<li><strong>Drug approvals:<\/strong> Pharma earnings follow product launches and approvals.<\/li>\n<li><strong>Footfall:<\/strong> Malls depend on consumer spending.<\/li>\n<li><strong>Valuation:<\/strong> Several names trade at premium multiples.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Risks_to_Keep_in_Mind_Before_Buying_Mumbai_Stocks\"><\/span><strong>Risks to Keep in Mind Before Buying Mumbai Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The first risk is that pharma earnings depend on product approvals, pricing and regulatory outcomes in export markets. The second is that engineering and mall businesses follow capex and consumer cycles. Valuations differ, so check each stock.<\/p>\n<p>On the numbers, Phoenix Mills trades at the highest P\/E on this list at 43.23, so its earnings need to keep growing to support the price. Mumbai stocks to buy can still fall when markets turn weak, and a staggered entry has historically suited investors better than a lump-sum purchase.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Choose_Mumbai_Stocks_to_Buy\"><\/span><strong>How to Choose Mumbai Stocks to Buy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Check growth:<\/strong> Look for steady revenue and profit growth.<\/li>\n<li><strong>Review margins:<\/strong> Stable margins show pricing power.<\/li>\n<li><strong>Study sector exposure:<\/strong> Pharma, engineering and malls differ.<\/li>\n<li><strong>Compare valuations:<\/strong> Premium multiples need steady results.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Mumbai_Stocks\"><\/span><strong>How to Invest in Mumbai Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ol>\n<li>Shortlist two or three companies from this list that match your risk appetite.<\/li>\n<li>Open the Univest Screener and compare P\/E, ROE and debt for each stock.<\/li>\n<li>Check the latest quarterly results and shareholding pattern on NSE or BSE.<\/li>\n<li>Decide an amount you can hold for three to five years and split it into two or three purchases.<\/li>\n<li>Review the holding after every quarterly result instead of reacting to daily price moves.<\/li>\n<\/ol>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Larsen and Toubro offers the lowest P\/E on this list at 25.06, Ajanta Pharma has the highest return on equity at 23.33%, and Ipca Laboratories posted the fastest net profit growth in its latest full year at 51.3%. Among the best Mumbai stocks in India, these five give investors a spread of size, valuation and growth, so the right pick depends on risk appetite and holding period. Spread the entry, keep position sizes sensible and consult a SEBI-registered advisor before investing in any of these Mumbai stocks to buy.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Mumbai_Stocks_to_Buy\"><\/span><strong>Frequently Asked Questions on Mumbai Stocks to Buy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Which_are_the_best_Mumbai_stocks_to_buy_in_November_2026\"><\/span><strong>Which are the best Mumbai stocks to buy in November 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The five Mumbai stocks on the November 2026 watchlist are Larsen and Toubro, Sun Pharmaceutical Industries, Phoenix Mills, Ajanta Pharma and Ipca Laboratories. Larsen and Toubro has the lowest P\/E at 25.06, Ajanta Pharma has the highest ROE at 23.33%, and Ipca Laboratories grew net profit 51.3% in its latest full year. This is educational content, not investment advice, so please consult a SEBI-registered advisor.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Larsen_and_Toubro_a_good_stock_to_buy_from_this_Mumbai_list\"><\/span><strong>Is Larsen and Toubro a good stock to buy from this Mumbai list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Larsen and Toubro is the largest company on this list with a market capitalisation of Rs 5,23,536 crore and a P\/E of 25.06 against an industry P\/E of 21.53. Its FY26 revenue rose 12.2% and net profit rose 8.3%, with return on equity at 15.81%. Whether it suits you depends on your risk appetite and holding period, so please consult a SEBI-registered advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Are_these_Mumbai_stocks_expensive_right_now\"><\/span><strong>Are these Mumbai stocks expensive right now?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Valuations vary across the group. Larsen and Toubro trades at a P\/E of 25.06, Sun Pharmaceutical Industries trades at a P\/E of 34.91, Phoenix Mills trades at a P\/E of 43.23, Ajanta Pharma trades at a P\/E of 38.10, Ipca Laboratories trades at a P\/E of 35.53, against industry multiples ranging from 21.53 to 37.65. Higher multiples reflect faster growth but also leave less room for earnings misses, so entry price deserves attention.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_these_Mumbai_stocks_pay_a_dividend\"><\/span><strong>Which of these Mumbai stocks pay a dividend?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dividend yields on this list are Larsen and Toubro 1.00%, Sun Pharmaceutical Industries 0.91%, Phoenix Mills 0.13%, Ajanta Pharma 0.81%, Ipca Laboratories 0.31%. Yields are modest across the group, so most investors look at these stocks for growth in earnings rather than for income, and payouts can change with company profits.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_stock_on_this_list_has_the_highest_return_on_equity\"><\/span><strong>Which stock on this list has the highest return on equity?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Ajanta Pharma has the highest ROE on this list at 23.33%, followed by Larsen and Toubro at 15.81% and Ipca Laboratories at 14.15%. A higher ROE shows a company earns more profit on shareholder capital, but it should be read alongside valuation and debt.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_risks_of_investing_in_Mumbai_stocks\"><\/span><strong>What are the risks of investing in Mumbai stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The main risks are regulatory outcomes in pharma, project and consumer cycles and premium valuations. On this list, Phoenix Mills trades at the highest P\/E of 43.23, which leaves less room for earnings disappointments. Staggered buying and a long holding period can help manage these risks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_can_I_invest_in_Mumbai_stocks_in_India\"><\/span><strong>How can I invest in Mumbai stocks in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> You can buy these stocks directly on NSE or BSE through a demat account, and compare them first on the Univest Screener using P\/E, ROE and debt. Many investors split the amount across two or three purchases and review the holding after each quarterly result. Sector-themed mutual funds and ETFs are another route for investors who prefer diversification.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Which are the best Mumbai stocks to buy in November 2026?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The five Mumbai stocks on the November 2026 watchlist are Larsen and Toubro, Sun Pharmaceutical Industries, Phoenix Mills, Ajanta Pharma and Ipca Laboratories. Larsen and Toubro has the lowest P\/E at 25.06, Ajanta Pharma has the highest ROE at 23.33%, and Ipca Laboratories grew net profit 51.3% in its latest full year. This is educational content, not investment advice, so please consult a SEBI-registered advisor.\"}},{\"@type\":\"Question\",\"name\":\"Is Larsen and Toubro a good stock to buy from this Mumbai list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Larsen and Toubro is the largest company on this list with a market capitalisation of Rs 5,23,536 crore and a P\/E of 25.06 against an industry P\/E of 21.53. Its FY26 revenue rose 12.2% and net profit rose 8.3%, with return on equity at 15.81%. Whether it suits you depends on your risk appetite and holding period, so please consult a SEBI-registered advisor before investing.\"}},{\"@type\":\"Question\",\"name\":\"Are these Mumbai stocks expensive right now?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Valuations vary across the group. Larsen and Toubro trades at a P\/E of 25.06, Sun Pharmaceutical Industries trades at a P\/E of 34.91, Phoenix Mills trades at a P\/E of 43.23, Ajanta Pharma trades at a P\/E of 38.10, Ipca Laboratories trades at a P\/E of 35.53, against industry multiples ranging from 21.53 to 37.65. Higher multiples reflect faster growth but also leave less room for earnings misses, so entry price deserves attention.\"}},{\"@type\":\"Question\",\"name\":\"Which of these Mumbai stocks pay a dividend?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dividend yields on this list are Larsen and Toubro 1.00%, Sun Pharmaceutical Industries 0.91%, Phoenix Mills 0.13%, Ajanta Pharma 0.81%, Ipca Laboratories 0.31%. Yields are modest across the group, so most investors look at these stocks for growth in earnings rather than for income, and payouts can change with company profits.\"}},{\"@type\":\"Question\",\"name\":\"Which stock on this list has the highest return on equity?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Ajanta Pharma has the highest ROE on this list at 23.33%, followed by Larsen and Toubro at 15.81% and Ipca Laboratories at 14.15%. A higher ROE shows a company earns more profit on shareholder capital, but it should be read alongside valuation and debt.\"}},{\"@type\":\"Question\",\"name\":\"What are the risks of investing in Mumbai stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The main risks are regulatory outcomes in pharma, project and consumer cycles and premium valuations. On this list, Phoenix Mills trades at the highest P\/E of 43.23, which leaves less room for earnings disappointments. Staggered buying and a long holding period can help manage these risks.\"}},{\"@type\":\"Question\",\"name\":\"How can I invest in Mumbai stocks in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"You can buy these stocks directly on NSE or BSE through a demat account, and compare them first on the Univest Screener using P\/E, ROE and debt. Many investors split the amount across two or three purchases and review the holding after each quarterly result. Sector-themed mutual funds and ETFs are another route for investors who prefer diversification.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Five Mumbai stocks on the November 2026 watchlist with FY26 growth, valuation, ROE, shareholding and risks for L&#038;T, Sun Pharma, Phoenix, Ajanta Pharma and Ipca Labs.<\/p>\n","protected":false},"author":38,"featured_media":338141,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[19434,19433,19432,812,627],"class_list":["post-338142","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-larsen-and-toubro","tag-mumbai-based-companies","tag-mumbai-stocks","tag-phoenix-mills","tag-sun-pharma"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["338141"],"rank_math_title":["Mumbai Stocks to Buy in Nov 2026: Top 5 Picks"],"rank_math_description":["Mumbai stocks to buy in November 2026: L&amp;T, Sun Pharma, Phoenix and Ajanta Pharma, with FY26 growth, valuation, ROE and key risks for each. Data as of 3 Nov 2026."],"rank_math_focus_keyword":["Mumbai stocks to buy"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/mumbai-stocks-to-buy-in-november-2026-5-names-on-the-watchlist.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/338142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=338142"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/338142\/revisions"}],"predecessor-version":[{"id":338143,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/338142\/revisions\/338143"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/338141"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=338142"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=338142"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=338142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}